Who Should Take Retatrutide? Ideal Candidate Profile

Retatrutide produced unprecedented weight loss in Phase 2 trials — an average of 24.2% body weight reduction at the highest dose (Jastreboff et al., NEJM 2023). But who is the ideal candidate for this triple-agonist medication? Understanding the clinical trial criteria, the patient populations being studied, and the unique properties of retatrutide helps identify who stands to benefit most from this next-generation treatment.

Phase 2 Trial Enrollment Criteria

The Phase 2 trial provides the best indication of who retatrutide is being developed for. Key inclusion criteria were:

• Age: Adults aged 18-75
• BMI: 30 or higher (obesity), or 27+ with at least one weight-related comorbidity
• No type 2 diabetes: The obesity trial excluded diabetic patients (a separate trial studied the diabetic population)
• Stable weight: No significant weight change in the 3 months prior to enrollment

Ideal Candidate Profiles

Based on the trial data and retatrutide's unique mechanism, several patient profiles stand out as potentially ideal candidates:

1. Patients Who Have Plateaued on Current GLP-1 Medications

If you are on semaglutide or tirzepatide and have reached a weight loss plateau short of your goal, retatrutide's additional glucagon receptor activation could help break through. The triple-agonist mechanism attacks obesity from an additional metabolic pathway that single and dual agonists do not address.

2. Patients with Fatty Liver Disease (MASH/NAFLD)

The Phase 2 trial showed retatrutide reduced liver fat by up to 86% — far exceeding what other medications achieve. The glucagon receptor directly promotes hepatic fat oxidation. For the estimated 100 million Americans with fatty liver disease, retatrutide may be uniquely effective. Eli Lilly is running a dedicated MASH/liver trial.

3. Patients with Severe Obesity (BMI 40+)

Patients with severe obesity often need the greatest weight loss to achieve meaningful health improvements. Retatrutide's 24% average at the highest dose gives these patients a realistic pharmaceutical pathway to losing 70-100+ pounds. Previously, bariatric surgery was the only option that could reliably produce this level of weight loss.

4. Patients with Type 2 Diabetes and Obesity

In a separate Phase 2 trial, retatrutide produced A1C reductions of up to 2.02% in patients with type 2 diabetes — among the largest reductions ever seen with an incretin-based therapy. Combined with significant weight loss, retatrutide could put many patients into diabetes remission.

5. Patients with Multiple Weight-Related Comorbidities

Patients dealing with a combination of obesity, high blood pressure, high cholesterol, sleep apnea, and joint pain stand to benefit from retatrutide's comprehensive metabolic effects. The Phase 2 trial showed improvements across cardiovascular markers, and dedicated trials are studying retatrutide for sleep apnea and osteoarthritis.

6. Patients Who Want to Avoid Surgery

For patients who are candidates for bariatric surgery but prefer a non-surgical approach, retatrutide offers a pharmaceutical alternative that approaches surgical-level results. With 54% of participants on the highest dose losing 25%+ of body weight, many patients could achieve surgery-equivalent outcomes.

Who Should NOT Take Retatrutide

Based on Phase 2 trial exclusion criteria and known pharmacological properties, the following groups are likely poor candidates for retatrutide:

Should You Wait or Start Now?

One of the most common questions is whether to wait for retatrutide or start treatment with currently available medications. For most patients, the answer is to start now. Here is why:

• Retatrutide is not yet available: Phase 3 trials are ongoing and FDA approval, if it comes, is likely 2026-2027 at the earliest
• Current medications are highly effective: Semaglutide produces 15-17% weight loss and tirzepatide produces 20-22% — both life-changing results
• Every month matters: Obesity-related health risks compound over time. Starting treatment now provides immediate health benefits
• Transitioning is possible: If retatrutide is approved, patients on semaglutide or tirzepatide could potentially switch

TRIMI offers compounded semaglutide starting at $125/month and compounded tirzepatide starting at $125/month. These are the same active ingredients as Wegovy and Zepbound, available at a fraction of the cost. Learn more about how the process works.

How to Prepare for Retatrutide

If retatrutide is your ultimate goal, here is how to prepare:

• Start a GLP-1 now: Experience with semaglutide or tirzepatide will help you and your provider understand how you respond to incretin-based therapies
• Build healthy habits: The patients who get the best results combine medication with nutrition and exercise changes
• Address comorbidities: Work with your doctor to manage blood pressure, blood sugar, and cholesterol now
• Follow the trials: Stay informed about TRIUMPH trial results as they are released